Table 5.
Difference of proportion of BRONJ in the drug groups (on the basis of the results of table 3)
| Drug groups | CLO intravenous (95% CI) | IBA oral (95% CI) | IBA intravenous (95% CI) | PAM (95% CI) | ALE (95% CI) | RIS (95% CI) | ZOL (95% CI) |
| CLO oral | OR: 1.5 (0.1 to 24.8), p=0.78 |
OR: 0.5
(0.3 to 0.9), p=0.02 |
OR: 0.2
(0.1 to 0.4), p≤ 0.001 |
OR: 1.8 (0.9 to 3.7), p=0.11 |
OR: 0.2
(0.1 to 0.3), p<0.001 |
OR: 0.1
(0.1 to 0.2), p<0.001 |
OR: 1.0 (0.7 to 1.6), p=0.85 |
| CLO intravenous* | OR: 0.3 (0.0 to 5.6), p=0.45 |
OR: 0.2 (0.0 to 2.7), p=0.20 |
OR: 1.2 (0.1 to 21.1), p=0.89 |
OR: 0.1 (0.0 to 2.0), p=0.14 |
OR: 0.1 (0.1 to 1.5), p=0.09 |
OR: 0.7 (0.0 to 11.2), p=0.79 |
|
| IBA oral |
OR: 0.5
(0.3 to 0.8), p=0.002 |
OR: 3.5
(1.7 to 7.1), p<0.001 |
OR: 0.4
(0.2 to 0.6), p<0.001 |
OR: 0.3
(0.2 to 0.4), p<0.001 |
OR: 2.1
(1.4 to 3.1), p<0.001 |
||
| IBA intravenous |
OR: 7.3
(3.7 to 14.2), p<0.001 |
OR: 0.8 (0.5 to 1.1), p=0.12 |
OR: 0.6
(0.4 to 0.9), p=0.006 |
OR: 4.3
(3.0 to 6.0), p<0.001 |
|||
| PAM |
OR: 0.1
(0.1 to 0.2), p<0.001 |
OR: 0.1
(0.0 to 0.1), p<0.001 |
OR: 0.6 (0.3 to 1.1), p=0.09 |
||||
| ALE | OR: 0.7 (0.5 to 1.0), p=0.08 |
OR: 5.6
(4.4 to 7.1), p<0.001 |
|||||
| RIS | OR: 7.6 (5.4 to 10.6), p<0.001 |
Bold values are statistically significant.
This table shows whether a drug has a stronger effect to develop BRONJ than the other one.
*In the case of intravenous CLO, 0.5 cases were added to each patients’ number in the equation to be able to count ORs.
ALE, alendronate; BRONJ, bisphosphonate-related osteonecrosis of the jaw; CLO, clodronate; IBA, ibandronate; PAM, pamidronate; RIS, risedronate; ZOL, zoledronic acid.